Fuisz Pharma Announces Patented Film Formulations For Enhanced Buccal Drug Delivery Performance

Fuisz Pharma Announces Patented Film Formulations For Enhanced Buccal Drug Delivery Performance

MIAMI, Oct. 2, 2012 /PRNewswire/ -- Fuisz Pharma announced today a patented film formulation for enhanced drug delivery performance. The seminal patent for this technology issued as United States Patent 8,241,661 ("Biocompatible Film with Variable Cross-Sectional Properties").

Joseph Fuisz Esq., managing member for Fuisz Pharma, explained: "It is understood that bi-layer film compositions can offer improved buccal absorption characteristics by retarding the drug that is lost to salivary flow and thereby is swallowed and diverted to the GI tract. Such drug is naturally not available for absorption at the intended buccal delivery site."
"At the same time, manufacturing two films – one for the drug and a second for a backing layer – and laminating said films is more difficult and costly than making a single film."

"What today's announcement deals with – and what is strongly covered by the issued patent claims of the '661 patent – is the intentional formation of hydrophobic domains in the top of a monolayer film. These hydrophobic domains retard the dissolution of the top section of the film, thereby precluding loss of drug to salivary flow. This offers the benefit of improved buccal performance with easier manufacturing and freedom to operate with respect to certain bi-layer patents."

Richard C. Fuisz, M.D. (http://en.wikipedia.org/wiki/Richard_Carl_Fuisz) commented: "Bottom line here is that we have bi layer functionality in a single layer cast film. In addition, by employing physical laws of miscibility and density, the way is open for more than one drug and/or for different release rates. It is to be decided whether this patent is licensed or utilized by Fuisz."

Fuisz Pharma is a private pharmaceutical technology company originated by the Fuiszes. The Fuiszes have made substantial contributions in drug delivery including orally dissolving tablets and novel particle coating systems at Fuisz Technologies; inventing and developing thin film drug delivery technologies at Kosmos Pharma and MonoSol Rx, as well as independently developing extruded sheet technology, and have extensive experience working with big and specialty pharma. Fuisz Pharma has its headquarters in Miami and is not affiliated with MonoSol Rx. www.fuisz.com.

SOURCE Fuisz Pharma